Pain can be defined as an unpleasant sensation that is transferred by the sensory neurons to the brain. The adversity of pain is not limited to physical sensations. According to International Association for the Study of Pain (IASP), it is a distressing sensory and emotional experience combined with potential tissue damage. There are four major types of pain, the one caused by nerve irritation known as neuropathic pain, the one that typically arises as the result of tissue injury known as nociceptive pain, the abnormal inflammation arises due to improper response by the immune system of the body known as inflammatory pain and lastly, functional pain which has no obvious origin. Pain is one of the major issues which deteriorates the health and as per studies and estimations 1 in every 5 adults suffer from pain. Moreover, it has been found that globally, 1 in 10 adults are diagnosed with chronic pain each year.
The pain can be experienced in any form, chronic, acute or intermittent. There are numerous causes of pain with cancer, post-operative pain, migraine, arthritis, post-operation and injuries being the major ones. According to a research study conducted in 2019, in the UK alone 13–50% of adults are already affected by chronic pain.
Pain management is an interdisciplinary approach which evaluates the pain, ease the suffering caused by the pain and improves the quality of life and health. The aid approach of pain management ranges from sudden pain issues such as headaches to many types of long-lasting pain such as low back pain. Pain management uses a range of medication to reduce or treat the pain and there are many underlying physiological mechanisms behind this. The medications may target nociceptors or prevents the injured or damaged cells from producing and releasing prostaglandin.
Pain management drugs performs actions in numerous ways to prevent, reduce, or stop pain sensations. According to Report Ocean study, the Global Pain Management Drugs market was approximately US$ 65,963.1 million in 2019 and is anticipated to reach $85,549.3 million by 2027 growing at a rate of 3.9% over the forecast period 2020-2027.
This report forecasts growth of Pain Management Drugs market at global level and provides an insight of the latest trends. For the current analysis, Report Ocean has segmented the market by drug class, by indication and by region.
· Drug class
v NS AIDs (Non-Steroidal Anti-Inflammatory Drugs)
v Anesthetics Antidepressants
v Anti-migraine Agents
v Arthritic Pain
v Neuropathic Pain
v Cancer Pain
v Chronic Back Pain
v Postoperative Pain
v North America
v Asia Pacific
Rise in geriatric population is the main factor that drives growth of the global pain management market, as this population pool often suffers from joint pain and other chronic conditions. Moreover, rise in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis further increases the market growth. As per the National Cancer Institute, almost 50% of cancer patients undergo moderate to severe pain. Furthermore, increasing surgical processes and rise in healthcare expenditure fuelled growth of the market. Contrary to this, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes restrains the market growth.
The largest contributor to the market in 2019 was opioids segment, due to rising prevalence of chronic conditions and high efficiency of opioids to relieve pain under these conditions. The anesthetics segment is expected to possess highest growth rate during the forecast period 2020-2027. By indication, the neuropathic pain segment accounted for largest market share in 2019 owing to presence of large patient population that increases demand for drugs and is expected to maintain that position in the forecast period. Cancer pain and chronic back pain segments are also expecting growth owing to rise in surgeries at global level and elevating prevalence of back pain causing chronic diseases.
Among the key regions taken into consideration for the study and analysis of the global pain management drug market, the leading country with large pool of aging population and well-regulated conditions was North America in 2019. However, due to elevated cases of drug abuse and addictive nature of opioids, the use of prescribed opioids has been decreased, leading to decline in opioid consumption for pain management. While, Asia-Pacific with larger patient pool and increased healthcare expenditure is anticipated to experience highest growth rate during the forecast period.
Major market players of Global Pain Management Drugs included in this report are the following:
· Abbott Laboratories
· Eli Lilly & Company
· Neurocrine Biosciences
· GlaxoSmithKline Plc.
· Johnson & Johnson
· Merck & Co. Inc.
· Mylan NV.
· Novartis AG
· Pfizer, Inc.
· Purdue Pharma L.P.
· Allergen Inc.
· Bayer AG
· Bristol-Myers Squibb
Anjeso, meloxicam injection developed by Baudax Bio has been approved by the FDA in February, 2020 for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It will be administered once-a-day through intravenous (IV) route. The active ingredient meloxicam possesses analgesic, anti-inflammatory and antipyretic activities that inhibit the cyclooxygenase type 2 pathway (COX-2), and subsequently reduces prostaglandin biosynthesis.
Emgality injection, developed by Eli Lilly and Company was initially approved in 2018 to prevent migraine, later in 2019 the same injection received further approval by the FDA for the treatment of episodic cluster headache in adults. It is the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache. These attacks may strike several times a day, lasting between 15 minutes and three hours.
Orilissa (elagolix), an oral treatment for the management of moderate to severe pain associated with endometriosis developed by Neurocrine Biosciences was approved by the FDA in August, 2018. Endometriosis is a common condition that affects approximately one in 10 women of reproductive age.
Exparel (bupivacaine liposome injectable suspension), developed by Pacira Pharmaceuticals, Inc. was initially approved in 2011 as a single use injection into a surgical site to produce post-surgery pain relief. However, in 2018 it was approved by the FDA to be used as a nerve block to help adult patients with pain management for 48 hours after shoulder surgery.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: